Omalizumab is effective in the long-term control of severe allergic asthma

1997

1997, British guidelines on asthma management: 1995 review and position statement, Thorax, 52, S1

Holt, 1999, The role of allergy in the development of asthma, Nature, 402, B12, 10.1038/35037009

Drazen, 1996, Sorting out the cytokines of asthma, J Exp Med, 183, 1, 10.1084/jem.183.1.1

Hamelmann, 1999, Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness – a murine model, Allergy, 54, 297, 10.1034/j.1398-9995.1999.00085.x

Spector, 1999, Allergic inflammation in upper and lower airways, Ann Allergy Asthma Immunol, 83, 435, 10.1016/S1081-1206(10)62848-7

Wills-Karp, 1999, Immunologic basis of antigen-induced airway hyperresponsiveness, Ann Rev Immunol, 17, 255, 10.1146/annurev.immunol.17.1.255

Williams, 2000, The diverse potential effector and immunoregulatory roles of mast cells in allergic disease, J Allergy Clin Immunol, 105, 847, 10.1067/mai.2000.106485

Busse, 2001, Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma, J Allergy Clin Immunol, 108, 184, 10.1067/mai.2001.117880

Owen, 2002, Anti-immunoglobulin E therapy for asthma, Pulm Pharmacol Ther, 15, 417, 10.1006/pupt.2002.0372